WO2007025069A3 - Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine - Google Patents

Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine Download PDF

Info

Publication number
WO2007025069A3
WO2007025069A3 PCT/US2006/033124 US2006033124W WO2007025069A3 WO 2007025069 A3 WO2007025069 A3 WO 2007025069A3 US 2006033124 W US2006033124 W US 2006033124W WO 2007025069 A3 WO2007025069 A3 WO 2007025069A3
Authority
WO
WIPO (PCT)
Prior art keywords
diazaspirodecane
receptor antagonists
orexin receptor
compounds
orexin receptors
Prior art date
Application number
PCT/US2006/033124
Other languages
English (en)
Other versions
WO2007025069A2 (fr
Inventor
Michael J Breslin
Christopher D Cox
David B Whitman
Original Assignee
Merck & Co Inc
Michael J Breslin
Christopher D Cox
David B Whitman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Michael J Breslin, Christopher D Cox, David B Whitman filed Critical Merck & Co Inc
Priority to US11/990,585 priority Critical patent/US20090176789A1/en
Priority to AU2006282955A priority patent/AU2006282955A1/en
Priority to CA002620124A priority patent/CA2620124A1/fr
Priority to EP06802269A priority patent/EP1922071A2/fr
Priority to JP2008528157A priority patent/JP2009506061A/ja
Publication of WO2007025069A2 publication Critical patent/WO2007025069A2/fr
Publication of WO2007025069A3 publication Critical patent/WO2007025069A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés de diazaspirodécane qui sont des antagonistes des récepteurs d'orexine, et qui sont utilisés dans le traitement ou la prévention de troubles et de maladies neurologiques et psychiatriques dans lesquels sont impliqués des récepteurs d'orexine. L'invention concerne également des compositions pharmaceutiques comprenant ces composés, ainsi que l'utilisation de ces composés et de ces compositions dans la prévention ou le traitement de maladies dans lesquelles sont impliqués des récepteurs d'orexine.
PCT/US2006/033124 2005-08-26 2006-08-24 Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine WO2007025069A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/990,585 US20090176789A1 (en) 2005-08-26 2006-08-24 Diazaspirodecane orexin receptor antagonists
AU2006282955A AU2006282955A1 (en) 2005-08-26 2006-08-24 Diazaspirodecane orexin receptor antagonists
CA002620124A CA2620124A1 (fr) 2005-08-26 2006-08-24 Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
EP06802269A EP1922071A2 (fr) 2005-08-26 2006-08-24 Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
JP2008528157A JP2009506061A (ja) 2005-08-26 2006-08-24 ジアザスピロデカンオレキシン受容体拮抗薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71175405P 2005-08-26 2005-08-26
US60/711,754 2005-08-26

Publications (2)

Publication Number Publication Date
WO2007025069A2 WO2007025069A2 (fr) 2007-03-01
WO2007025069A3 true WO2007025069A3 (fr) 2007-10-18

Family

ID=37772404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033124 WO2007025069A2 (fr) 2005-08-26 2006-08-24 Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine

Country Status (6)

Country Link
US (1) US20090176789A1 (fr)
EP (1) EP1922071A2 (fr)
JP (1) JP2009506061A (fr)
AU (1) AU2006282955A1 (fr)
CA (1) CA2620124A1 (fr)
WO (1) WO2007025069A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049110B1 (fr) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Diazépans pontés antagonistes du récepteur de l'oréxine
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
RU2470021C2 (ru) 2007-05-23 2012-12-20 Мерк Шарп Энд Домэ Корп. Пиридилпиперидиновые антагонисты рецептора орексинов
EP2150115B1 (fr) 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
JP2010155827A (ja) * 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
EP2275421A1 (fr) * 2009-07-15 2011-01-19 Rottapharm S.p.A. Composés spiro-aminés utiles pour le traitement de, entre autres, troubles du sommeil et de la toxicomanie
EP2491038B1 (fr) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Octahydropyrrolo[3,4-c]pyrroles disubstitués en tant que modulateurs de récepteur d'orexine
JP5848251B2 (ja) * 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
JP5847087B2 (ja) * 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
CN102070633B (zh) * 2009-11-24 2013-04-10 上海药明康德新药开发有限公司 一种带保护基的1,8-二氮杂螺[4,5]葵烷的合成方法
CN102762567A (zh) * 2009-12-21 2012-10-31 诺瓦提斯公司 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
CA2863413A1 (fr) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Piperidines/prolines substituees en tant qu'antagonistes du recepteur de l'orexine
AR101558A1 (es) 2014-08-13 2016-12-28 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
TWI710557B (zh) 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
CA2960253A1 (fr) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methodes de traitement de la depression au moyen d'antagonistes du recepteur orexine-2
WO2017194548A1 (fr) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
JP7455133B2 (ja) * 2018-09-27 2024-03-25 シェンチェン チップスクリーン バイオサイエンシズ カンパニー、リミテッド インドールアミン－２，３－ジオキシゲナーゼ阻害活性を有するキノロン誘導体
WO2023204291A1 (fr) * 2022-04-22 2023-10-26 住友ファーマ株式会社 Dérivé de bicycloamine carboxamide
US20240116892A1 (en) * 2022-08-08 2024-04-11 Ajax Therapeutics, Inc. Heterocyclic amide and urea compounds as jak2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577425A (en) * 1967-12-11 1971-05-04 Yoshitomi Pharmaceutical 8-(1,4-benzodioxan-2-ylmethyl)-3-oxo-1-thia-4,8-diazaspiro(4,5)decanes
US5739336A (en) * 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US20050026915A1 (en) * 2001-11-27 2005-02-03 Devita Robert J. 2-Aminoquinoline compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577425A (en) * 1967-12-11 1971-05-04 Yoshitomi Pharmaceutical 8-(1,4-benzodioxan-2-ylmethyl)-3-oxo-1-thia-4,8-diazaspiro(4,5)decanes
US5739336A (en) * 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US20050026915A1 (en) * 2001-11-27 2005-02-03 Devita Robert J. 2-Aminoquinoline compounds

Also Published As

Publication number Publication date
WO2007025069A2 (fr) 2007-03-01
JP2009506061A (ja) 2009-02-12
US20090176789A1 (en) 2009-07-09
CA2620124A1 (fr) 2007-03-01
AU2006282955A1 (en) 2007-03-01
EP1922071A2 (fr) 2008-05-21

Similar Documents

Publication Publication Date Title
WO2007025069A3 (fr) Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
WO2007061763A3 (fr) Antagonistes des recepteurs de l’indole orexine
WO2007126934A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés amidoéthylthioéther
WO2007126935A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés diazépane
WO2008008551A3 (fr) Prolines bis-amides substituées en 2 antagonistes du récepteur de l'oréxine
WO2008008517A3 (fr) Diazépans pontés antagonistes du récepteur de l'oréxine
SI2049529T1 (sl) Substituiran diazepan oreksin receptor antagonist
MX2009005712A (es) Antagonistas de receptor de orexina de diazepam sustituido.
WO2007019234A3 (fr) Antagonistes des recepteurs d'orexine a base de sulfamide d'aminoethane
HK1134084A1 (en) Pyridyl piperidine orexin receptor antagonists
WO2007067511A3 (fr) Antagonistes de recepteur de prokineticine de morpholine-carboxamide
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
WO2006091496A3 (fr) Potentialisateurs de benzazole de recepteurs de glutamate metabotropique
WO2006014918A3 (fr) Potentialisateurs d'acetophenone heterocycliques de recepteurs metabotropiques du glutamate
WO2007002884A3 (fr) 4-fluoro-piperidines antagonistes du canal calcium de type t
WO2004087649A3 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
WO2006047237A3 (fr) Potentialisateurs indanone heterocycliques des recepteurs metabotropiques du glutamate
WO2007002361A3 (fr) Antagonistes du canal calcique de type t 3-fluoro-piperidine
WO2007061696A3 (fr) Antagonistes du recepteur gcrp bicyclique du spirolactam
WO2007061695A3 (fr) Antagonistes du recepteur cgrp biclyclique de spirohydantoine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11990585

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006282955

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2620124

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006802269

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008528157

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006282955

Country of ref document: AU

Date of ref document: 20060824

Kind code of ref document: A